Recent progresses in diagnostic and therapeutic methods have significantly improved prognosis in cancer patients. However, cancer is still considered as one of the main causes of human deaths in the world. Late diagnosis in advanced tumor stages can reduce the effectiveness of treatment methods and increase mortality rate of cancer patients. Therefore, investigating the molecular mechanisms of tumor progression can help to introduce the early diagnostic markers in these patients. MicroRNA (miRNAs) has an important role in regulation of pathophysiological cellular processes. Due to their high stability in body fluids, they are always used as the non-invasive markers in cancer patients. Since, miR-363 deregulation has been reported in a wide range of cancers, we discussed the role of miR-363 during tumor progression and metastasis. It has been reported that miR-363 has mainly a tumor suppressor function through the regulation of transcription factors, apoptosis, cell cycle, and structural proteins. MiR-363 also affected the tumor progression via regulation of various signaling pathways such as WNT, MAPK, TGF-β, NOTCH, and PI3K/AKT. Therefore, miR-363 can be introduced as a probable therapeutic target as well as a non-invasive diagnostic marker in cancer patients.
Keyphrases
- cell proliferation
- pi k akt
- cell cycle
- long non coding rna
- poor prognosis
- cell cycle arrest
- signaling pathway
- long noncoding rna
- oxidative stress
- endothelial cells
- randomized controlled trial
- type diabetes
- stem cells
- ejection fraction
- induced apoptosis
- cardiovascular events
- prognostic factors
- risk factors
- epithelial mesenchymal transition
- young adults
- endoplasmic reticulum stress
- coronary artery disease
- cell death
- patient reported outcomes